Compare Gilead Sciences, Inc. (GILD) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs UiPath Inc — how do they compare? Gilead Sciences, Inc. trades at $135.1 (market cap $163.51B), while UiPath Inc trades at $12.05 (market cap $6.19B). The key difference: Gilead Sciences, Inc. is far larger — about 26.4× UiPath Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| GILD | PATH | |
|---|---|---|
Market Cap | $163.51B | $6.19B |
Sector | Health | Technology |
52-Week High | $155.80 | $19.29 |
52-Week Low | $108.22 | $9.38 |
Enterprise Value | $178.05B | $4.97B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
UiPath (PATH) trades at $11.81, down 1.09% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q4 2025 EPS of $0.30, beating estimates, but missed in Q1 2026. Revenue growth is strong, reaching $1.43B in 2025, with improving net margins from -58.91% in 2022 to -5.16% in 2025. Analysts maintain a consensus price target of $13.33, suggesting upside potential. Recent news highlights agentic AI advancements with Maestro Case launches.
PATH presents a growth opportunity with robust revenue expansion and margin improvement, though profitability remains negative. Risks include execution on AI monetization and competitive pressures. The stock's current pullback may offer an attractive entry point, supported by bullish analyst sentiment and technical indicators, but investors should weigh near-term earnings volatility against long-term automation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
